OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock.

A number of other analysts have also commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research report on Thursday, May 16th. Stephens restated an “equal weight” rating and set a $4.00 price objective on shares of OncoCyte in a research note on Wednesday, April 17th. Finally, Benchmark reaffirmed a “speculative buy” rating and issued a $5.00 target price on shares of OncoCyte in a research report on Monday, April 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, OncoCyte has an average rating of “Hold” and an average target price of $4.06.

OncoCyte Stock Up 5.7 %

Shares of NASDAQ OCX opened at $3.33 on Thursday. The company has a fifty day moving average price of $2.83 and a 200 day moving average price of $2.91. OncoCyte has a 1-year low of $2.08 and a 1-year high of $4.70.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) earnings per share for the quarter. OncoCyte had a negative return on equity of 135.45% and a negative net margin of 2,905.14%. The firm had revenue of $0.18 million for the quarter. As a group, sell-side analysts forecast that OncoCyte will post -2.58 earnings per share for the current fiscal year.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.